ABUS - Arbutus Biopharma Corp Stock Price, Fair Value and News

2.87USD-0.02 (-0.69%)Market Closed

Market Summary

USD2.87-0.02

Market Closed

-0.69%

ABUS Stock Price

View Fullscreen

ABUS RSI Chart

ABUS Valuation

Market Cap

545.4M

Price/Earnings (Trailing)

-7.33

Price/Sales (Trailing)

EV/EBITDA

-6.67

Price/Free Cashflow

-6.91

ABUS Price/Sales (Trailing)

ABUS Profitability

EBT Margin

-547.54%

Return on Equity

-64.89%

Return on Assets

-49.49%

Free Cashflow Yield

-14.47%

ABUS Fundamentals

ABUS Revenue

Revenue (TTM)

13.0M

Rev. Growth (Yr)

-77.09%

Rev. Growth (Qtr)

-28.58%

ABUS Earnings

Earnings (TTM)

-74.4M

Earnings Growth (Yr)

-9.4%

Earnings Growth (Qtr)

7.44%

Breaking Down ABUS Revenue

Last 7 days

2.9%

Last 30 days

-1.0%

Last 90 days

-0.4%

Trailing 12 Months

13.4%

How does ABUS drawdown profile look like?

ABUS Financial Health

Current Ratio

6.69

ABUS Investor Care

Shares Dilution (1Y)

13.59%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.0M	0	0	0
2023	33.1M	23.5M	22.2M	18.1M
2022	21.5M	33.4M	36.0M	39.0M
2021	7.5M	8.4M	10.2M	11.0M
2020	6.2M	6.5M	6.7M	6.9M
2019	5.2M	4.6M	9.5M	6.0M
2018	11.9M	12.1M	6.8M	5.9M
2017	3.8M	6.1M	8.4M	10.7M
2016	19.0M	13.2M	7.3M	1.5M
2015	15.2M	16.8M	16.5M	24.9M
2014	17.8M	16.7M	18.1M	15.0M
2013	17.9M	17.1M	16.3M	15.5M
2012	17.1M	17.5M	17.9M	18.3M
2011	20.2M	19.0M	17.8M	16.6M
2010	0	0	0	21.4M
2009	0	0	0	14.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arbutus Biopharma Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 02, 2024	sims karen	sold	-10,077	2.3125	-4,358	chief medical officer
Feb 02, 2024	mcelhaugh michael j.	sold	-23,504	2.3125	-10,164	interim president & ceo
Feb 02, 2024	sofia michael j.	sold	-23,083	2.3125	-9,982	chief scientific officer
Feb 02, 2024	hastings david c	sold	-22,183	2.3125	-9,593	chief financial officer
Feb 01, 2024	sims karen	acquired	-	-	101,000	chief medical officer
Feb 01, 2024	mcelhaugh michael j.	acquired	-	-	123,800	interim president & ceo
Feb 01, 2024	sofia michael j.	acquired	-	-	109,500	chief scientific officer
Feb 01, 2024	naftzger j. christopher	acquired	-	-	95,100	general counsel and cco
Feb 01, 2024	hastings david c	acquired	-	-	112,500	chief financial officer
Feb 01, 2023	collier william h.	acquired	-	-	216,500	president and ceo

Which funds bought or sold ABUS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	BANK OF MONTREAL /CAN/	reduced	-5.11	-22,322	872,431	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	5.01	589,785	7,634,770	-%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	reduced	-6.04	231	4,923	-%
May 13, 2024	Pathstone Holdings, LLC	unchanged	-	812	26,200	-%
May 13, 2024	FMR LLC	added	0.3	14,512	427,872	-%
May 13, 2024	Lighthouse Investment Partners, LLC	new	-	255,562	255,562	0.01%
May 13, 2024	Nuveen Asset Management, LLC	unchanged	-	23,531	758,922	-%
May 13, 2024	UBS Group AG	reduced	-3.68	-2,084	347,844	-%
May 13, 2024	Creative Planning	added	105	40,624	77,039	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.85	3,655	161,093	-%

Are Funds Buying or Selling ABUS?

Are funds buying ABUS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABUS

No. of Funds

Unveiling Arbutus Biopharma Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	two seas capital lp	5.4%	9,041,927	SC 13G/A
Feb 14, 2024	whitefort capital management, lp	7.9%	13,197,062	SC 13G/A
Feb 12, 2024	blackrock inc.	6.2%	10,390,300	SC 13G/A
Nov 21, 2023	two seas capital lp	5.7%	9,503,103	SC 13G
Sep 11, 2023	whitefort capital management, lp	6.0%	10,013,899	SC 13G
Feb 03, 2023	blackrock inc.	5.6%	8,700,392	SC 13G
Feb 14, 2022	rtw investments, lp	1.7%	2,504,493	SC 13G/A
Oct 20, 2021	roivant sciences ltd.	29.1%	38,847,462	SC 13D/A
Feb 16, 2021	foresite capital fund iv, l.p.	0%	0	SC 13G/A
Feb 12, 2021	rtw investments, lp	7.05%	5,978,355	SC 13G/A

Recent SEC filings of Arbutus Biopharma Corp

View All Filings

Date Filed	Form Type	Document
May 09, 2024	SC 13D	13D - Major Acquisition
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Apr 04, 2024	8-K	Current Report
Mar 05, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Arbutus Biopharma Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

Arbutus Biopharma Corp News

Latest updates

Arbutus Biopharma Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-28.6%	1,532,000	2,145,000	4,658,000	4,651,000	6,687,000	6,245,000	5,952,000	14,241,000	12,581,000	3,206,000	3,340,000	2,329,000	2,113,000	2,386,000	1,523,000	1,514,000	1,491,000	3,988,500	6,486,000	653,000	679,000
Operating Expenses	-8.7%	20,895,000	22,892,000	26,216,000	23,036,000	24,100,000	28,807,000	23,763,000	28,350,000	23,555,000	24,002,000	21,748,000	20,971,000	17,789,000	18,687,000	16,740,000	14,655,000	14,638,000	14,653,000	94,086,000	21,298,000	19,875,000
S&GA Expenses	-100.0%	-	5,101,000	5,842,000	5,980,000	5,552,000	4,249,000	3,493,000	5,200,000	4,892,000	4,597,000	4,183,000	4,478,000	3,878,000	3,661,000	4,065,000	3,566,000	3,553,000	1,877,000	3,249,000	8,189,000	4,412,000
R&D Expenses	-12.3%	15,403,000	17,564,000	20,169,000	17,692,000	18,275,000	22,949,000	20,055,000	22,942,000	18,462,000	19,212,000	16,709,000	15,799,000	13,782,000	16,392,000	12,065,000	10,465,000	10,416,000	12,418,000	17,731,000	12,740,000	14,712,000
EBITDA Margin	-40.0%	-5.34	-3.82	-3.10	-2.67	-1.71	-1.51	-1.63	-1.80	-2.89	-6.13	-6.60	-7.94	-	-	-	-	-	-	-	-	-
Interest Expenses	0%	44,000	44,000	46,000	171,000	198,000	309,000	429,000	482,000	506,000	560,000	762,000	763,000	772,000	797,000	1,074,000	1,099,000	1,041,000	994,000	1,100,000	2,000	12,000
Income Taxes	-	-	-	-	-	-	-	-	-	4,444,000	-	-	-	-	-	-	-	-	-	-12,656,000	-	-
Earnings Before Taxes	-	-	-	-20,104,000	-17,094,000	-16,339,000	-	-17,567,000	-14,192,000	-11,321,000	-	-19,158,000	-19,387,000	-16,381,000	-17,042,000	-18,755,000	-14,087,000	-13,861,000	-24,654,000	-95,159,000	-23,315,000	-23,251,000
EBT Margin	-39.7%	-5.48	-3.92	-3.20	-2.77	-1.79	-1.60	-1.73	-1.92	-3.09	-6.55	-7.08	-8.57	-	-	-	-	-	-	-	-	-
Net Income	7.4%	-17,875,000	-19,312,000	-20,104,000	-17,094,000	-16,339,000	-21,932,000	-17,567,000	-14,192,000	-15,765,000	-21,321,000	-19,158,000	-19,387,000	-16,381,000	-17,042,000	-18,755,000	-14,087,000	-13,861,000	-24,654,000	-82,503,000	-23,315,000	-23,251,000
Net Income Margin	-42.6%	-5.73	-4.02	-3.39	-3.10	-2.11	-1.78	-1.91	-2.11	-3.52	-6.94	-7.08	-8.57	-	-	-	-	-	-	-	-	-
Free Cashflow	-12.1%	-19,390,000	-17,292,000	-21,816,000	-20,418,000	-27,418,000	-17,124,000	-18,783,000	-20,505,000	20,544,000	-19,664,000	-16,056,000	-14,641,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.1%	150	144	159	177	191	195	204	216	237	204	166	135	146	137	131	98.00	103	106	117	193	209
Current Assets	2.9%	136	132	142	159	153	151	141	158	173	161	127	83.00	137	128	121	86.00	88.00	94.00	94.00	100	112
Cash Equivalents	64.0%	43.00	26.00	18.00	27.00	41.00	31.00	24.00	47.00	81.00	109	78.00	31.00	79.00	52.00	97.00	46.00	26.00	32.00	90.00	79.00	84.00
Net PPE	-5.6%	4.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	7.00	7.00	7.00	7.00	8.00	8.00	9.00	9.00	9.00	10.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.00	22.00
Liabilities	-7.1%	36.00	38.00	39.00	42.00	47.00	59.00	58.00	63.00	71.00	35.00	35.00	35.00	32.00	35.00	34.00	32.00	29.00	33.00	34.00	28.00	28.00
Current Liabilities	-9.7%	20.00	22.00	22.00	25.00	25.00	33.00	28.00	30.00	32.00	11.00	10.00	9.00	7.00	10.00	8.00	6.00	4.00	8.00	9.00	9.00	9.00
Shareholder's Equity	8.1%	115	106	119	135	144	137	146	153	166	169	130	101	114	102	97.00	66.00	73.00	73.00	84.00	164	181
Retained Earnings	-1.4%	-1,294	-1,276	-1,257	-1,237	-1,220	-1,203	-1,181	-1,164	-1,150	-1,134	-1,112	-1,088	-1,065	-1,045	-1,025	-1,004	-986	-970	-942	-857	-831
Additional Paid-In Capital	-1.3%	80.00	81.00	80.00	77.00	74.00	72.00	71.00	69.00	67.00	65.00	64.00	64.00	62.00	61.00	60.00	58.00	57.00	55.00	55.00	54.00	50.00
Accumulated Depreciation	3.0%	12.00	12.00	12.00	11.00	11.00	11.00	10.00	10.00	10.00	9.00	9.00	8.00	8.00	8.00	7.00	7.00	9.00	6.00	9.00	8.00	7.00
Shares Outstanding	6.1%	180	170	168	167	165	157	151	149	148	145	101	95.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	288	-	-	-	290	-	-	-	238	-	-	-	130	-	-	-	118	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-11.6%	-19,295	-17,292	-21,784	-19,559	-27,301	-16,990	-18,692	-20,293	20,619	-19,606	-16,036	-14,009	-17,881	-15,013	-12,174	-8,801	-15,453	-13,351	-23,470	-17,605	-16,580
Share Based Compensation	16.9%	2,014	1,723	2,483	2,964	2,131	1,667	1,715	2,064	1,736	1,431	1,615	1,743	1,635	1,431	1,688	1,597	1,445	-23.00	1,516	3,784	1,522
Cashflow From Investing	-47.4%	11,694	22,225	10,429	1,441	16,678	12,682	-13,738	-13,830	-60,056	-8,121	15,969	-38,747	18,221	-49,976	14,097	23,371	-2,401	-58,822	16,155	9,972	61,033
Cashflow From Financing	541.7%	24,430	3,807	1,681	4,742	20,417	11,084	9,132	113	11,485	59,121	46,952	4,289	26,874	20,210	49,096	4,959	12,481	13,893	18,549	2,479	2,536

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABUS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Revenues	$ 1,532	$ 6,687
Operating expenses
Research and development	15,403	18,275
General and administrative	5,312	5,552
Change in fair value of contingent consideration	180	273
Total operating expenses	20,895	24,100
Loss from operations	(19,363)	(17,413)
Interest income	1,545	1,268
Interest expense	(44)	(198)
Foreign exchange gain	(13)	4
Total other income	1,488	1,074
Net loss	$ (17,875)	$ (16,339)
Loss per share
Basic (in USD per share)	$ (0.10)	$ (0.10)
Diluted (in USD per share)	$ (0.10)	$ (0.10)
Weighted average number of common shares
Basic (in shares)	175,625,552	161,643,404
Diluted (in shares)	175,625,552	161,643,404
Comprehensive loss
Unrealized gain on available-for-sale securities	$ 50	$ 854
Comprehensive loss	(17,825)	(15,485)
Collaborations and licenses
Revenue
Revenues	939	5,509
Non-cash royalty revenue
Revenue
Revenues	$ 593	$ 1,178

ABUS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 43,101	$ 26,285
Investments in marketable short-term securities	86,139	99,718
Accounts receivable	2,139	1,776
Prepaid expenses and other current assets	4,493	4,248
Total current assets	135,872	132,027
Property and equipment, net of accumulated depreciation of $12,256 (December 31, 2023: $11,900)	4,414	4,674
Investments in marketable securities, non-current	8,677	6,284
Right of use asset	1,327	1,416
Total assets	150,290	144,401
Current liabilities:
Accounts payable and accrued liabilities	8,247	10,271
Deferred license revenue, current	11,547	11,791
Lease liability, current	502	425
Total current liabilities	20,296	22,487
Liability related to sale of future royalties	6,396	6,953
Contingent consideration	7,780	7,600
Lease liability, non-current	1,181	1,343
Total liabilities	35,653	38,383
Stockholders’ equity
Issued and outstanding: 180,192,227 (December 31, 2023: 169,867,414)	1,377,315	1,349,821
Additional paid-in capital	80,220	81,270
Deficit	(1,294,527)	(1,276,652)
Accumulated other comprehensive loss	(48,371)	(48,421)
Total stockholders’ equity	114,637	106,018
Total liabilities and stockholders’ equity	$ 150,290	$ 144,401

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

CEO	Mr. William H. Collier
WEBSITE	arbutusbio.com
INDUSTRY	Biotechnology
EMPLOYEES	96

Arbutus Biopharma Corp Frequently Asked Questions

What is the ticker symbol for Arbutus Biopharma Corp? What does ABUS stand for in stocks?

ABUS is the stock ticker symbol of Arbutus Biopharma Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arbutus Biopharma Corp (ABUS)?

As of Mon May 13 2024, market cap of Arbutus Biopharma Corp is 545.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers. The fair value of Arbutus Biopharma Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arbutus Biopharma Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arbutus Biopharma Corp a good stock to buy?

The fair value guage provides a quick view whether ABUS is over valued or under valued. Whether Arbutus Biopharma Corp is cheap or expensive depends on the assumptions which impact Arbutus Biopharma Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABUS.

What is Arbutus Biopharma Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ABUS's PE ratio (Price to Earnings) is -7.33 and Price to Sales (PS) ratio is 42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABUS PE ratio will change depending on the future growth rate expectations of investors.